Clinical Programs
Myeloid Therapeutics is a clinical stage company with multiple programs including Primed and ATAK Monocytes that address high unmet need cancers.
MT-201
Glioblastoma
DISCOVERY
LEAD OPTIMIZATION
IND-ENABLING
PHASE 1
We are advancing our glioblastoma program to clinical stage in partnership with Duke University after showing potent anti-tumor activity in animal cancer models.
Cell Therapy Programs
Using a harmonized, one-day manufacturing process, we are moving into the clinic with our ATAK monocytes. These myeloid cells are engineered with a novel CAR design that triggers tumor-specific phagocytosis and secretion of pro-inflammatory cytokines, resulting in a hot tumor microenvironment and causing tumor cell death. In addition, ATAK monocytes sustain the ability to cross-present antigens, generating a durable anti-tumor response by cytotoxic T cells.
MT-101
T Cell Lymphoma
DISCOVERY
LEAD OPTIMIZATION
IND-ENABLING
PHASE 1
MT-101 is being developed for the treatment of relapsed and refractory CD5-expressing T cell lymphomas. Refractory PTCL is a lethal disease with limited treatment options, that until now has not benefited from innovations in cell therapy.
In vitro and in vivo studies show MT-101 demonstrated meaningful anti-tumor activity. Treatment in these models has been associated with potent phagocytosis responses, the production of inflammatory mediators and delays in tumor progression.
MT-102
HER2+ Solid Tumors
DISCOVERY
LEAD OPTIMIZATION
IND-ENABLING
PHASE 1
MT-102 is being developed for individuals with HER2 expressing cancers. In vivo studies show MT-102 has eradicated HER2+ tumors.
MT-103
TROP2 Solid Tumors
DISCOVERY
LEAD OPTIMIZATION
IND-ENABLING
PHASE 1
MT-103 targets tumors with TROP2 antigen.